Patients at standard risk for fungal infections

Indication	First Choice	Alternatives
Prophylaxis for a) allogeneic HCT recipients; or b) autologous HCT recipients who have or will have prolonged neutropenia and mucosal damage from intense conditioning regimens, graft manipulation, or who have recently received purine analogues. Note: Administer prophylaxis from the start of conditioning (or day of transplantation for advanced-generation azoles) until engraftment (ie, approximately 30 days after HCT) or until 7 days after the absolute neutrophil count >1000 cells/ mm3	Fluconazole Adult/Adolescents: 400 mg orally or i.v. daily (AI) Pediatrics: Children 6 months to 13 years: 3–6 mg/kg/day orally or i.v., maximum dose 600 mg per day (AI)	Adults/Adolescents: Fluconazole, 200 mg orally or i.v. daily (BI) Itraconazole, oral solution 200 mg orally twice daily (CI); Micafungin, 50 mg i.v. once daily (BI); Voriconazole, 4 mg/kg twice daily i.v. or 200 mg twice daily orally (BI); Posaconazole, 200 mg orally 3 times daily (BI) Pediatrics: None

HCT indicates hematopoietic cell transplantation.